Biotech entity
gene-therapy is the sole category represented across all 1 tracked stories. BioLargo, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Rumble Inc., all published on March 9, 2026.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 1 tracked stories. BioLargo, Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Rumble Inc., all published on March 9, 2026. Each carries 5 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rumble Inc.. Shared-story counts are live from our verified record — not editorial picks.
REGENXBIO reported a wider-than-expected Q4 2025 loss of $1.30 per share, missing analyst estimates of $1.01. The results reflect a broader trend of financial pressure on high-growth biotech and life science firms as they navigate late-stage clinical and commercial transitions.
Rumble Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
